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ABSTRACT 
The scaffold protein A kinase anchor protein 12 (AKAP12) exerts tumor suppressor 
activity and is downregulated in several tumor entities. We aimed to characterize 
AKAP12 expression and regulation in astrocytomas including pilocytic and diffusely 
infiltrating astrocytomas. We examined 194 human gliomas and 23 white matter 
normal brain samples by immunohistochemistry or immunoblotting for AKAP12 
expression. Quantitative methylation analysis of the AKAP12 promoter by 
MassARRAY® of normal brain, astrocytomas of WHO-grade I-IV and glioma cell lines 
was performed followed by restoration experiments using 5-aza-2’deoxycytidine. Our 
results show that AKAP12 is expressed in a perivascular distribution in normal CNS, 
strongly upregulated in pilocytic astrocytomas and weakly expressed in diffuse 
astrocytomas of WHO grade II-IV. Methylation analyses revealed specific 
hypermethylation of AKAP12α promoter in astrocytomas of WHO grade II-IV. 
Consequently, restoration experiments decreased AKAP12α promoter methylation 
and drastically increased AKAP12α mRNA levels in primary glioblastoma cells. In 
summary, we could show that AKAP12 is differentially expressed in human 
astrocytomas showing high expression in pilocytic but low expression in diffuse 
astrocytomas of all WHO-grades. Our results further indicate that epigenetic 
mechanisms are involved in silencing AKAP12 in diffuse astrocytomas, however a 
differential tumor suppressive role of AKAP12 in distinct astrocytoma subtypes 
remains to be determined. 
 
Keywords: astrocytoma, AKAP12, Gravin, SSeCKS, promoter methylation. 
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INTRODUCTION 
The scaffold protein A kinase anchor protein 12 (AKAP12; synonymous to AKAP250 
and Gravin or to its rodent ortholog SSeCKS) is a central mediator of protein kinase 
A and protein kinase C signalling (1, 2). AKAP12 acts as a tumor suppressor and its 
expression is frequently downregulated in human malignancies. However, the 
molecular mechanisms responsible for reduced AKAP12 expression are poorly 
understood (3). To date, AKAP12 related tumor suppressive properties in neoplasms 
including gastric, liver and prostate cancer were linked to (i) inhibition of myosin light 
chain kinase (MLCK) mediated cytokinesis, (ii) suppression of the migratory potential 
by inhibiting the Raf/MEK/Erk pathway and matrix metalloproteinase-2 and -9 (MMP-
2/-9), (iii) induction of apoptosis by regulating CDKI-cyclin D1 and caspase-3 and (iv) 
reduction of the angiogenic and metastatic capacity by inhibiting VEGF (vascular 
endothelial growth factor) (4-10). Recently, we demonstrated that AKAP12 is 
downregulated in hepatocarcinogenesis by hypermethylation of the AKAP12 
promoter pointing to a primary epigenetic alteration being involved in AKAP12 
mediated tumorigenesis (6). Under non-neoplastic conditions, the VEGF opposing 
effects of AKAP12 are involved in development and maintenance of the blood-brain 
barrier (BBB) and CNS angiogenesis (11, 12). Due to its anti-angiogenic and anti-
migratory properties, we hypothesized that deregulation of AKAP12 may be involved 
in the development of malignant gliomas characterized by diffuse infiltration and high 
angiogenic potential. Malignant gliomas account for approximately 70% of adult 
malignant primary brain tumors and survival is closely related to WHO grade (13). 
Patients suffering from high grade astrocytomas show short survival times being as 
low as 1.6 years in anaplastic astrocytoma and 0.4 years in glioblastoma in 
population-based studies (14). High grade gliomas are treatment refractory despite 
multimodal treatment including neurosurgical resection followed by combined radio-
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/chemotherapy, a feature which is closely related to VEGF-mediated 
neovascularization and MMP-mediated glioma cell migration (15-17). Therefore, new 
targeted therapeutic options focusing on anti-angiogenesis entered clinical trials 
frequently in neurooncology (18). However, at least half of patients fail to respond to 
anti-angiogenic treatment and time to progression is short (19). Adverse effects of 
anti-angiogenic therapy such as formation of microsatellite metastases were 
identified and linked to increased migratory-invasive potential of glioma cells (20, 21). 
Although neovascularization is a hallmark of malignant progression in diffuse 
gliomas, non-diffuse pilocytic astrocytomas also frequently exhibit proliferating blood 
vessels and show a good clinical prognosis indicating distinct ways of neo-
angiogenesis (22). Since AKAP12 is a potent VEGF-antagonist, we aimed at defining 
its expression pattern, regulation, and clinical impact in astrocytomas of different 
WHO grades to determine its potential involvement in malignant transformation and 
progression in human astrocytomas.  
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MATERIALS AND METHODS 
Patient characteristics and tissue specimens  
194 brain tumor samples obtained from the tissue bank of the Institute of Brain 
Research, University of Tuebingen, including 26 WHO grade I (pilocytic), 37 WHO 
grade II, 52 grade III astrocytomas and 79 glioblastomas (WHO grade IV) were 
investigated (for summary see Table 1). For WHO grade IV tumors, 25 infiltration 
zones and 31 relapses were included as well as 23 autopsy cases without any CNS 
pathologies serving as normal controls. Utilization of specimens was approved by the 
University’s ethics commission. Neuropathological diagnoses were confirmed by two 
neuropathologists (RM, MM). The histopathological typing and grading was 
performed according to the WHO criteria for tumors of the nervous system (23). The 
same samples which were analysed in the neuropathological diagnostical setting 
were also used for immunohistochemical analyses. Median follow-up for each 
astrocytoma subtype is given in Table 1. Edema levels were analyzed in T2 MRI or 
CCT scans. The association of AKAP12 and edema (no=0/low=1/high=2) was semi-
quantitatively assessed by ordinal regression analysis. Edema scores were analyzed 
in cooperation with the Department of Neuroradiology (University of Tuebingen). 
 
Immunohistochemistry 
Specimens were fixed in buffered formalin (4% formaldehyde; pH 7.4) and embedded 
in paraffin. Immunohistochemical analysis was performed according to routine 
protocols using the ABC method and diaminobenzidine as chromogen. In order to 
detect AKAP12, a polyclonal goat IgG antibody (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA; dilution 1:200) was applied. Sections were counterstained with 
hemalaun. Antibody staining was initially established on testis and prostate tissue. 
Specificity was controlled by omission of the AKAP12-specific antibody and addition 
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of non-immunized goat IgG sera. Double immunohistochemical stainings were 
performed using an automated immunostaining system with standard protocols 
(Ventana, Strasbourg, France). The following antibodies were used: (i) AKAP12 
(clone 1C5; mouse monoclonal; 1:10000; Sigma, Hamburg, Germany); (ii) CD31 
(clone JC70A; mouse monoclonal; 1:200; DAKO, Hamburg, Germany); (iii) collagen 
IV (clone CIV 22; mouse monoclonal; 1:50; DAKO), (iv) GFAP (polyclonal; rabbit; 
1:10000; DAKO) and α-SMA (clone 1A4; mouse monoclonal; 1:500; DAKO. A 28 min 
incubation with one drop of Universal Secondary Antibody was added (Ventana). For 
diaminobenzidine (DAB) visualization, the sections were incubated with one drop of I-
View SA-HRP for 16 min and then with DAB/H2O2 for 8 min. The sections were 
incubated with a copper enhancer (Ventana) for 4 min. The application of one drop of 
Activator R CM and one drop of Naphtol CM (Ventana) for 4 min was followed by the 
visualization with one drop of Fast Red CM (Ventana) twice for 8 min. Finally, all 
sections were washed, counterstained with hematoxylin and mounted. 
 
Immunofluorescence 
To define the main source of AKAP12 protein expression in human astrocytic 
tumours and normal CNS tissue, immunofluorescent stainings were performed using 
the following antibodies: (i) for endothelia: CD31 (clone JC70A; mouse monoclonal; 
1:200; DAKO), (ii) for basement membrane structures: collagen IV (clone CIV 22; 
mouse monoclonal; 1:50; DAKO) and (iii) for AKAP12 (abcam; JP74; mouse 
monoclonal; 1:10000). Subsequently, the following secondary ABs were used: Alexa 
Fluor488 (goat-anti-mouse IgG2a, Invitrogen, Darmstadt, Germany; dilution 1:500) 
and Alexa Fluor568 (goat-anti-mouse IgG1, Invitrogen; dilution 1:500). Nuclear 
counterstaining was performed using Topro-3 (dilution: 1:1000; Invitrogen). 
Fluorescence images were analyzed and recorded on a Nikon C1si (Nikon, Japan) 
Kommentar [MM1]: IDH1 analyses ? 
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confocal microscope, using the EZ-C1 software. After recording, digital images were 
further processed and adjusted for brightness, contrast and color balance. 
 
Light microscopy and counting 
To quantify AKAP12 immunoreactivity of a single sample, 200 cells per tumor were 
counted; a clear cytoplasmic or membranous stain was rated as positive. Blood 
vessels, intraluminal cells and cells which unequivocally could be referred to neurons 
or inflammatory cells by means of morphology were excluded. Immunohistochemical 
stainings were evaluated and photographically documented using an Olympus BX50 
light microscope. 
 
Immunoblotting 
The fresh frozen tissues used for immunoblotting were also evaluated by 2 
neuropathologists (PNH and MM) before preparing the lysates. Only samples 
showing a tumor cell amount of > 70% as well as none or only a minimum amount of 
necroses were selected for immunoblotting. Immunoblotting was performed using the 
following primary antibodies: a goat polyclonal anti-AKAP12 (dilution 1:1000; Santa 
Cruz Biotechnology) and a mouse monoclonal anti-AKAP12 antibody (dilution 
1:1000; Abcam, Cambridge, MA). For detailed information see supplemental 
material.  
 
Cell culture and reagents 
The human malignant glioma cell lines LN-18, U138MG, U87MG, LN-428, D247MG, 
T98G, LNT-229, A172, U251MG and U373MG were kindly provided by N. de Tribolet 
(University Hospital, Lausanne, Switzerland). As LN-229 cells used in different 
laboratories differ by their p53 status, the p53 wild-type LN-229 cells used in our 
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experiments were renamed LNT-229 for clarification (T for Tuebingen). Cells were 
cultured in 75 cm2 Falcon plastic flasks using DMEM supplemented with 1% 
glutamine (Life Technologies, Paisley, United Kingdom), 10% FCS (Biochrom, Berlin, 
Germany), and penicillin (100 IU/ml)/streptomycin (100 µg/ml). For 
immunocytochemical analyses, cells were centrifuged, fixed in buffered formalin (4% 
formaldehyde; pH 7.4) and embedded in paraffin. Subsequent immunohistochemical 
staining procedures were performed as described for human tissue. Primary human 
glioblastoma cell (NCH82, NCH89 and NCH440, provided by B. Campos) were 
cultured in high glucose DMEM (Life Technologies) supplemented with 10% FCS 
(24). DNA demethylation treatment was performed with 2 µmol/l 5-aza-2’-
deoxycytidine (Sigma-Aldrich, St.Louis, MO). Cells were treated with 5-aza-2’-
deoxycytidine for 72 hours, refreshing the media every 24 hours.  
 
DNA and RNA isolation 
DNA/RNA from fresh frozen tumor tissues or cell lines was isolated using the AllPrep 
DNA/RNA Mini kit (Qiagen, Hilden, Germany). 
 
MassARRAY® methylation analysis 
Quantitative DNA methylation analysis was performed by MassARRAY® technique. 
Genomic DNA from patients, healthy controls, or cell lines was chemically modified 
with sodium bisulfite using the EZ methylation kit (Zymo Research, Orange, CA, 
USA) and polymerase chain reaction (PCR) amplified. Regions for quantitative DNA 
methylation analysis covered the CpG islands around the respective transcription 
start sites of the two AKAP12 isoforms α and β (6). The PCR product was transcribed 
in vitro, cleaved by RNase A, and subjected to MALDI-TOF mass spectrometry 
analysis to determine methylation patterns (25). Methylation levels of long 
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interspersed nucleotide elements (LINE-1) were analyzed to obtain an estimate for 
global DNA methylation changes after 5-aza-2’-deoxycytidine treatment (26, 27). 
DNA methylation standards (0% to100% (in 20% steps) methylated genomic DNA) 
were used to control for potential PCR bias. The methylation results are displayed as 
a heat map using the Multiple Experimental Viewer software (Version 4.3) (28). 
Primer sequences are listed in Supplemental Table 1. 
 
cDNA synthesis and quantitative real-time PCR 
1 µg of purified DNase-treated RNA was transcribed to cDNA with Superscript™ II 
Reverse Transcriptase (Invitrogen, Darmstadt, Germany) using oligo-dT primers. 
Quantitative Real-Time PCR expression analyses were performed on the Roche 
Lightcycler© 480 system using the LightCycler® 480 Probes Master (both Roche 
Diagnostics, Mannheim, Germany). Expression of target genes (see Supplemental 
Table 2) was normalized to three housekeeping genes (ACTB, GAPDH and HPRT1). 
 
Statistical analysis  
To stabilize variances, fractions of AKAP12-positive cells were transformed by taking 
the arcsine of the square-root. Means were compared by one-way analysis of 
variance (ANOVA). For post-hoc testing Tukey-Kramer’s HSD test was used with a 
global significance level of 5%. For individual pairwise comparisons we used a one 
sample t-test. Back-transformed means are given together with their 95% confidence 
intervals (CI). To describe patient survival, univariate and multivariate survival 
analyses for censored data were performed. Expression and methylation differences 
in cell line experiments were statistically assessed by a two-sided t-test. Statistical 
analyses were performed using JMP 8.0 software (SAS, Cary, NC, USA). 
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RESULTS 
AKAP12 is selectively overexpressed in human pilocytic astrocytomas as compared 
to diffusely infiltrating astrocytomas.  
In normal human CNS areas (Fig. 1A), AKAP12 expression is almost exclusively 
found in a perivascular distribution whereas glial cells and neurons remain AKAP12-
negative (Fig. 1A). In WHO grade I pilocytic astrocytomas, AKAP12 is also strongly 
expressed at small residual capillaries and activated or proliferating blood vessels. 
However, most neoplastic cells display a strong cytoplasmic AKAP12 expression as 
well (Fig. 1B). In human WHO grade II diffuse astrocytomas, AKAP12 is again 
predominantly found at blood vessels (Fig. 1C). Single neoplastic cells within WHO 
grade II gliomas show a faint AKAP12 expression, to a far lower extent as compared 
to their pilocytic counterparts. In WHO grade III anaplastic astrocytomas (Fig. 1D, E) 
and glioblastomas (Fig. 1F-H) AKAP12 is heterogeneously expressed at blood 
vessels while being partly absent in glioma cells (Fig. 1D, G, H). Apart from 
astrocytes, which were predicted to be a major source of AKAP12 expression in the 
brain, we identified blood vessel associated mural cells (pericytes/smooth muscle 
cells) as a source of AKAP12 while endothelial cells mainly remain AKAP12-negative 
(supplemental Fig. 1-3).  
 
 
AKAP12 is significantly upregulated in pilocytic astrocytomas as compared to diffuse 
gliomas.   
For semiquantitative analyses, ratios of AKAP12-positive astrocytoma cells in relation 
to all cells were calculated for each glioma specimen (Fig. 2). WHO grade I pilocytic 
astrocytomas showed AKAP12 expression in 57.2 % (CI 45.7-68.3 %) of tumor cells, 
which was significantly elevated as compared to all diffuse astrocytoma variants 
(p<0.0001 for all comparisons). AKAP12 expression showed a slight non-significant 
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increase from grade II to IV gliomas. While only 16.7 % (CI 10.5-24.1 %) of cells in 
WHO grade II astrocytomas displayed an AKAP12-positivity, 21.6 % (CI 15.5-28.4 %) 
of WHO grade III astrocytoma cells and 25.3 % (CI 20-31.1 %) of WHO grade IV 
glioblastoma cells showed AKAP12 immunoreactivity. In glioblastomas, no significant 
changes of AKAP12 expression in recurrences were seen as compared to their 
primary counterpart (data not shown). To corroborate our quantification of the 
immunohistochemical analyses, lysates from WHO grade I to IV astrocytoma cryo 
specimens as well as normal control samples were analyzed for AKAP12 expression 
by immunoblotting. In line with the immunohistochemical findings, AKAP12 levels 
were strongly upregulated only in WHO grade I pilocytic astrocytoma samples, 
whereas samples of WHO grade II-IV diffuse gliomas and normal CNS control 
tissues showed similarly low AKAP12 expression levels (Fig. 3 and supplemental 
Fig. 4).  
 
AKAP12 expression is not associated with patient survival or edema formation in 
astrocytomas 
We correlated AKAP12 expression for a potential association with patient survival in 
both univariate and multivariate analyses, taking patient age, gender, extent of 
resection, tumor localization, Karnofsky index, WHO grade and AKAP12 levels in the 
latter without obtaining a significant association for AKAP12 expression and patient 
survival (data not shown). No differences in AKAP12 expression levels between IDH1 
mutated and wild-type tumors were observed (data not shown). As AKAP12 is 
supposed to be involved in the regulation of the BBB under non-neoplastic 
conditions, we further analyzed our cohort for a potential association of AKAP12 
expression and edema formation assessed by MRI. However, no significant changes 
were observed (data not shown). 
 
 
12 
AKAP12 expression is regulated by DNA promoter methylation. 
In a cohort of 424 glioblastomas (publicly available platform at the US National 
Institute of Health: The Cancer Genome Atlas Data Portal (http://tcga-
data.nci.nih.gov/tcga/tcgaHome2.jsp, assessed July 14th 2012) recently analyzed by 
genome wide human SNP array the AKAP12 gene locus on chromosome 6q24-25.2 
showed chromosomal losses (log2 ratio < -0.5) in 9.7 % (29). Strikingly, none of the 
cases showed chromosomal gains. Furthermore, no AKAP12 mutations were found 
in the TCGA data portal. Therefore, these data do not sufficiently explain the low 
AKAP12 expression levels in glioblastomas. As a possible suppressive mechanism, 
we investigated the DNA methylation of promoter related CpG islands of both 
AKAP12 isoforms in normal human CNS specimens, WHO grade I to IV 
astrocytomas as well as in various glioma cell lines and primary glioma cells by 
quantitative MassARRAY® analysis. In diffuse astrocytomas samples, 
hypermethylation was detected in the AKAP12α promoter (Fig. 4A, B), and less 
pronounced in the AKAP12β promoter (supplemental Fig. 5). For the AKAP12α 
promoter, a mean methylation of 77% for diffuse astrocytomas WHO grade II, 80% 
for anaplastic astrocytomas WHO grade III, 56% glioblastomas was recorded, while 
pilocytic astrocytomas showed a mean methylation of 19%. The level of AKAP12α 
promoter methylation was not associated with the mutational status of the IDH1/2 
gene within the group of diffusely infiltrating astrocytomas (supplemental Fig. 6). We 
additionally analyzed histologically normal brain tissue, observing a mean 
methylation of 35%. Most glioma cell lines (n=11) showed highly elevated (>80%) 
DNA methylation levels of the AKAP12α promoter (Fig. 4). Only two glioma cell lines 
showed a methylation status of below 80% (NCH89: 70%, U87MG: 41%). Low levels 
of AKAP12α promoter methylation were associated with higher AKAP12 protein 
expression levels (supplemental Fig. 7). Most of the GBM cell lines showed low or 
Kommentar [GB2]: Ich kenn mich bei 
den Zellen nicht aus, aber falls eine 
anaplastic cell line darunter ist, muss man 
GBM weiter oben auch anpassen, oder?! 
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not detectable methylation values concerning the AKAP12β promoter. 
(supplemental Fig. 5). 
 
AKAP12 is re-expressed in glioma cells upon treatment with demethylating agents 
To verify the functional relationship between promoter hypermethylation and loss of 
AKAP12 gene expression, methylation and mRNA expression levels of both isoforms 
were compared before and after treatment with 5-aza-dC in three primary GBM cell 
lines (NCH82, NCH89 and NCH440). The 5-aza-dC treatment resulted in a 
significantly decreased AKAP12α promoter methylation in the highly methylated GBM 
cell lines (Fig. 5A) accompanied by a significant increase in AKAP12α mRNA (Fig. 
5B) and protein (supplemental Fig. 8) expression, strongly suggesting a direct 
relationship between AKAP12α expression and methylation of its promoter. 
Treatment with 5-aza-dC also induced expression of AKAP12β in primary glioma 
cells (supplemental Fig. 9). Furthermore, we determined average methylation levels 
of LINE-1 repeat elements before and after 5-aza-dC treatment (Fig. 5C). The 
significant decrease in global LINE-1 methylation showed positive treatment 
response to the demethylating agent in GBM cell lines, as LINE-1 methylation was 
shown to be representative of genome-wide methylation status (27).  
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DISCUSSION 
Tumor suppressive activity of AKAP12 and its down-regulation associated with tumor 
progression and increased malignancy have been demonstrated in several 
malignancies (4, 6, 9), but in gliomas, the role of AKAP12 is almost completely 
unknown. On the one hand, it has been shown that AKAP12 controls maintenance of 
the BBB and CNS angiogenesis in a VEGF-opposing manner under non-neoplastic 
conditions (11, 12). On the other hand, AKAP12 constitutes a candidate gene 
potentially involved in the development of malignant gliomas harbouring a highly 
angiogenic potential. In this study, we show that AKAP12 is also localized in the 
perivascular space of normal brain vessels (Fig. 1). These findings are in line with 
previous reports from animal experiments that SSeCKS (the rodent AKAP12 
orthologue)-expressing astrocytes closely interact with ZO-1 expressing blood 
vessels by inhibiting VEGF expression via reduction of AP-1 and induction of the 
antipermeability factor Ang-1 leading to vessel quiescence (12). In our large cohort of 
194 human astrocytomas, we still observed AKAP12 expression in the perivascular 
distribution in most astrocytomas of all WHO grades (Fig. 1). In contrast, in WHO 
grade III anaplastic astrocytomas and WHO grade IV glioblastomas, AKAP12-
negative blood vessels were also observed. In addition to astrocytic end-feet, which 
have been previously reported to be responsible for AKAP12 expression under non-
neoplastic conditions, we could define vessel associated mural cells as another 
cellular source of AKAP12 (supplemental Fig. 1-3). The finding of AKAP12-negative 
blood vessels in higher grade astrocytomas might be related to immature BBB 
properties partially lacking mature mural cells and/or properly functioning astrocytic 
endfeet (30, 31). In addition to its differential expression in the perivascular space, 
AKAP12 expression was inhomogeneously distributed in astrocytoma cells. While in 
the group of diffusely growing astrocytomas, only a low percentage of approximately 
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20% of all cells exhibited only weak to moderate AKAP12 levels, more than 50% of 
all tumor cells in WHO grade I pilocytic astrocytomas displayed a strong AKAP12 
expression (Fig. 1 and 2). Since expression characteristics and functional data 
obtained in prostate, gastric, and hepatic cancer suggest a tumor suppressive 
function of AKAP12, its significant downregulation in the majority of diffuse 
astrocytomas as compared to WHO grade I pilocytic astrocytomas may correspond 
to malignant transformation which is in line with the clinical course of diffuse 
astrocytomas (4, 6, 9). The constantly high AKAP12 expression in slowly growing, 
curable pilocytic astrocytomas may reflect a preserved AKAP12 anti-tumoral activity. 
The similar AKAP12 protein expression levels in all diffuse astrocytomas and normal 
CNS tissue samples obtained from immunoblotting analyses is likely to result from a 
dilution effect related to the fact that normal CNS shows strong AKAP12 expression 
at the glial-vascular junctions while diffuse astrocytomas display much lower AKAP12 
expression levels, however on a slightly higher absolute number of tumor cells (Fig. 
1-3 and supplemental Fig. 4). Since TCGA analysis showed chromosomal losses of 
the AKAP12 locus in only 9.7% of human glioblastomas and no AKAP12 mutations 
are known for pilocytic astrocytomas, these genetic data do not explain the distinct 
AKAP12 expression differences in the different astrocytoma subgroups (32, 33). To 
further analyze the potentially underlying mechanism of differential AKAP12 
expression in astrocytoma subtypes, we analyzed their promoter methylation pattern 
since the AKAP12 gene is a target for epigenetic silencing in gastric, hepatocellular 
and lung cancer (4, 6, 34). Our study demonstrates that hypermethylation of 
AKAP12α promoter is specific for human diffuse astrocytoma tissue samples and 
various GBM cell lines (Fig. 4). Thus, gene silencing by promoter hypermethylation 
may be the cause for the significant decrease of AKAP12 protein levels in GBM cells. 
Although existing antibodies fail to distinguish between AKAP12 isoforms, data on 
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AKAP12α and β transcripts suggest that hypermethylation of the AKAP12α promoter 
is responsible for epigenetic silencing of AKAP12 (6). This is supported by the fact 
that highly methylated primary GBM cell lines with decreased AKAP12α promoter 
methylation showed increased expression of AKAP12α mRNA and protein 
expression after 5-aza-dC treatment (Fig. 5 and supplemental Fig. 7). Interestingly, 
we determined that even a small decrease in average AKAP12α methylation can 
result in a strong increase in mRNA expression levels in the GBM cell lines. This 
finding may suggest that only a fraction of primary GBM cells in the treated pool show 
AKAP12α reactivation due to promoter demethylation, resulting in an exponential 
increase in transcript abundance, further emphasizing the importance of epigenetic 
regulation in AKAP12 expression control. 
In contrast to the distinct hypermethylation of only the AKAP12α promoter in 
hepatocellular carcinoma, this finding was not observed in human astrocytoma (6). 
However, the AKAP12α and β promoter region was not hypermethylated to the same 
extent in our cohort, as seen e.g. in gastric cancer (4). Moreover, since the observed 
methylation pattern shows hypermethylation in all WHO grades of diffuse 
astrocytomas but not in pilocytic astrocytoma as compared to normal CNS tissue, this 
is likely to reflect a tumor-relevant epigenetic regulation in the development of 
astrocytoma subtype, although pilocytic astrocytomas share most transcriptional 
network changes with high grade gliomas except for single repressed pathways and 
specific genetic alterations (35, 36). Taken together, the findings of aberrant AKAP12 
expression and its functionally relevant epigenetic modulation in human astrocytomas 
constitute a novel differential epigenetic methylation pattern showing lower 
methylation rates in pilocytic but higher methylation rates in the group of diffuse 
astrocytomas WHO grade II-IV. Finally, the presented data indicate a coordinate 
control between the AKAP12 promoters in association with the development of 
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distinct astrocytoma subtypes. Further functional studies are needed to elucidate the 
putative tumor suppressive role of AKAP12 in human astrocytomas. 
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FIGURE LEGENDS 
Figure 1: AKAP12 is selectively overexpressed in human pilocytic astrocytomas as 
compared to the normal CNS and diffusely infiltrating astrocytomas.  
(A-F) Immunohistochemical analysis in normal human CNS tissue and human 
astrocytomas of different WHO grades reveals AKAP12 expression in (A) normal 
brain samples in a perivascular localization (arrow) while the surrounding CNS tissue 
remains negative. (B) In WHO grade I pilocytic astrocytomas, apart from the still 
perivascular expression (arrow), most tumor cells strongly exhibit AKAP12 
expression (inset: isotype control). (C) In WHO grade II diffuse astrocytomas, 
AKAP12 is predominantly localized in the perivascular space (black arrows) while 
most tumor cells (white arrows) display only a very subtle AKAP12 expression. In 
WHO grade III anaplastic astrocytomas (D, E) and glioblastomas (F-H), absent to 
moderate AKAP12 expression levels are seen on tumor cells while blood vessel were 
either AKAP12-positive (D, G, H, arrows), while AKAP12-negative blood vessels 
were also observed (E, F, arrows). (scale bar = 50 µm for all images).  
 
Figure 2: AKAP12 is significantly upregulated in human WHO grade I pilocytic 
astrocytomas as compared to the group of diffuse astrocytomas WHO grade II-IV. 
Quantification of relative proportions of AKAP12-positive tumor cells as determined 
by means of immunohistochemical analyses. The means of ratios of AKAP12 cell 
populations in each WHO grade were compared by a one-way analysis of variance 
(ANOVA) and for the post-hoc testing Tukey-Kramer’s HSD test was used with a 
global significance level of 5%. (*** = p<0.0001 as compared to WHO grade I 
pilocytic astrocytomas).  
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Figure 3: Immunoblotting of AKAP12 in WHO grade I-IV human astrocytoma and 
normal brain. 
Immunoblotting of AKAP12 in whole tissue lysates from randomly selected cases of 
WHO grade I-IV human astrocytomas and normal brain showing a selective 
upregulation in WHO grade I astrocytomas. β-actin served as a loading control.  
 
Figure 4: The AKAP12α promoter is significantly hypermethylated in diffuse human 
astrocytomas of WHO grade II-IV as compared to WHO grade I pilocytic 
astrocytomas.  
(A) Quantitative DNA methylation analysis of the AKAP12α promoter region in 
normal brain (NB), pilocytic astrocytoma (PA), astrocytoma WHO grade II/III (II/III), 
primary glioblastoma samples (GBM) and GBM cell lines (CL). Each column 
represents the CpGs island analyzed; each row represents one patient sample. 
Percentages of methylation span from 0% to 100%. (B) The average percentage of 
methylation is blotted for each sample represented in (A). Horizontal bars represent 
average methylation values for each group. WHO grade II-III diffuse astrocytomas 
and primary WHO grade IV glioblastoma samples show statistically significant 
hypermethylation as compared to WHO grade I pilocytic astrocytoma (*** = p<0.001; 
** = p=0.0034 in Mann-Whitney U test).  
 
Figure 5: AKAP12α is re-expressed in primary glioblastoma cells upon treatment 
with the demethylating agent 5-aza-2’-deoxycytidine.  
(A) Primary glioblastoma cells (NCH82, NCH89, and NCH440) were treated with 0 
µmol/l (-DAC) or 2 µmol/l (+DAC) of the demethylating agent 5-aza-2’-deoxycytidine 
(DAC) for 72 hours. AKAP12α promoter methylation was determined before and after 
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treatment (n=3). (B) Quantitative real-time PCR showing upregulation of isoform 
AKAP12α transcript relative to ACTB, GAPDH and HPRT1 after 72h 5-aza-2’-
deoxycytidine treatment (n=3). (C) LINE-1 serving as internal positive control for 
demethylation experiments (n=3).  
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Supplementary Tables: 
 
Supplementary Table 1: Primers used for methylation experiments. 
 
 
 
 
 
 
 
 
Touch-down PCRs were performed (10 cycles with a range of temperatures decreasing of -0.5°C at each cycle, and 37 or 40 cycles at the final low 
temperature). 
 
 
Supplementary Table 2: Primers used for mRNA expression determination. 
 
Isoform Amplicon size (bp) 
Forward primer 
5’-->3’ 
Reverse primer 
5’-->3’ 
Number 
of cycles 
Annealing 
temperature (°C) 
AKAP12α 79 AACGGTCAAGGAGCCCTAAA CATCTTCAGAGTCTCTCTGTCCAA 45 60 
AKAP12β 89 CCGCTAAGCTGATCTCCTGT CATCTTCAGAGTCTCTCTGTCCAA 45 60 
ActinB 76 ATTGGCAATGAGCGGTTC GGATGCCACAGGACTCCAT 45 60 
HPRT1 102 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 45 60 
TBP 119 AGCCAAGAGTGAAGAACAGTCC CACAGCTCCCCACCATATTC 45 60 
 
AKAP12α and AKAP12β expression values were normalized against the average expression of the three house-keeping genes ActinB, HPRT1 and TBP for 
the mRNAs from cell lines and ActinB and HPRT1 for the mRNAs from CNS/glioma tissues. 
 
 
 
 
Isoform Amplicon Amplicon size (bp) Left primer Right primer 
Number 
of cycles 
Annealing 
temperature 
range (°C) 
AKAP12-α A1 196 GTAGAGGTGGTTTGGATGGGTA CAAACCACRAATAAAATAAACCAC 10+37 6156 
AKAP12-β B1 460 AAGTTGAGATATAGAAGTATTAGT CCTAATCTCCTACCTACCAAC 10+37 6156 
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Supplementary Information to Material and Methods: 
 
Immunoblotting. 
The preparation of total protein lysates, subsequent SDS-PAGE and Western 
immunoblotting were performed using the following antibodies: goat polyclonal anti-
AKAP12 (dilution 1:1000; Santa Cruz Biotechnology) and a mouse monoclonal anti-
AKAP12 antibody (dilution 1:1000; Abcam). Primary antibodies were diluted in TBST (5 % 
milk powder) and incubated at 4°C overnight. Equal loading of protein samples was 
confirmed via β-actin detection using a mouse monoclonal anti-actin antibody (dilution 
1:10000, MP Biomedicals, Illkirch, France). Membranes were then incubated with a 
peroxidase (HRP) conjugated corresponding secondary antibody (dilution 1:2000; all from 
Cell Signaling Technology, Boston, MA) at room temperature for 1 h. Detection was 
performed using the chemiluminescence reagent Western Lightning® (Perkin Elmer, 
Rodgau, Germany). Blots were visualized and densitometrical analyses were performed 
using the FluorChem® SP Imaging System and the AlphaEase® FC Software (Alpha 
Innotech, San Leandro). 
 
Genetic analyses for IDH-1/2 mutation 
The IDH1 mutational status was assessed in all tumors samples by a mutation-specific 
monoclonal antibody for the IDH1 R132H mutation in tumor samples as described 
previously (1). Cases lacking the R132H mutation were assessed by direct sanger 
sequencing of the relevant exon for other rare IDH1 and IDH2 mutations using primer pairs 
as described in (2). DNA was extracted from GBM tissue sections using a BlackPREP 
FFPE kit (Analytik Jena, Germany), according to the manufacturer’s instructions, from 
paraffin blocks microscopically controlled for at least 70% tumor content.  
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1) Schittenhelm J. Mittelbronn M. Meyermann R. et al. Confirmation of R132H mutation of 
isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma. 
Acta Neuropathol 2011;122:651-2. 
2) Hartmann C. Meyer J. Balss J. et al. Type and frequency of IDH1 and IDH2 mutations 
are related to astrocytic and oligodendroglial differentiation and age: a study of 1.010 
diffuse gliomas. Acta Neuropathol 2009;118:469-74. 
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Supplemental Figure legends: 
 
Supplemental Fig. 1: Immunofluorescent analyses of AKAP12 in the normal human brain.   
Immunofluorescent stainings of normal brain tissue show a similar expression pattern of 
collagen IV and AKAP12 indicating that AKAP12 is expressed in perivascular areas where 
basement membranes are present. In contrast, no co-expression of CD31-positive 
endothelial cells and AKAP12 was observed indicating a lack of AKAP12 expression in the 
respective cell type.  
 
Supplemental Fig. 2: Immunofluorescent analyses of AKAP12 in glioblastomas.  
In line with the findings in normal human brain samples, AKAP12 - if present in 
glioblastomas - was also most strongly expressed in areas where vessel associated 
collagen IV-positive basement membranes were present surrounding CD31-positive 
endothelial cells.   
 
Supplemental Fig. 3: Mural cells of blood vessels in glioblastomas are a source of 
AKAP12 expression.  
AKAP12 is co-expressed in α-SMA-positive cells in glioblastoma-associated vessels 
indicating that mural cells (pericytes/smooth muscle cells) are a major source of AKAP12 
expression between areas where collagen IV-positive basement membranes are present. In 
contrast, GFAP-positive glioblastoma cells and CD31-positive endothelial cells are mainly 
AKAP12-negative.  
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Supplemental Fig. 4: AKAP12 protein expression is strongly upregulated in pilocytic 
astrocytomas.  
Immunoblotting of AKAP12 in whole tissue lysates from randomly selected cases of WHO 
grade I-IV human astrocytomas showing a selective upregulation in WHO grade I 
astrocytomas. β-actin served as loading control. 
 
Supplemental Fig. 5: AKAP12β promoter methylation status in human astrocytomas. 
There is a trend for AKAP12β promoter hypermethylation in diffuse human astrocytomas of 
WHO grade II-IV as compared to WHO grade I pilocytic astrocytomas although not reaching 
statistical significance. The average percentage of methylation is blotted for each sample of 
the AKAP12β promoter region. Horizontal bars represent average methylation values for 
each group. Normal brain (NB), pilocytic astrocytoma (PA), astrocytomas (WHO II-III) / 
primary GBM samples (GBM) and GBM cell lines (CL). 
 
Supplemental Fig. 6: IDH1/2 mutations are not associated with AKAP12α promoter 
methylation levels.  
Methylation levels of human astrocytomas of WHO grade I-IV are depicted according to the 
IDH1/2 mutation status. First, astrocytomas were assessed for expression of the mutant 
IDH1 (R132H) protein. For negative cases, sanger sequencing for mutation in the IDH1/2 
gene was performed.  
 
Supplemental Fig. 7: AKAP12 protein expression correlates with the AKAP12 promoter 
methylation status in glioma cell lines.  
AKAP12 immunocytochemistry of FFPE glioma cell lines is depicted. Glioma cell lines with 
high AKAP12α promoter methylation levels (LN-18 is shown as an example of this group) 
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present with marked lower AKAP12 protein expression levels as compared to a strong 
AKAP12 protein expression seen in glioma cells with considerably lower AKAP12α 
promoter methylation status (U87MG is shown as an example of this group).  
 
Supplemental Fig. 8: Reactivation of AKAP12 protein expression in primary glioblastoma 
cells upon demethylation treatment.  
Primary glioblastoma cell lines NCH82 and NCH440 were treated with 0µmol/l (-DAC) or 
2µmol/l (+DAC) 5-aza-2’-deoxycytidine for 72h. Immunoblotting for AKAP12 protein is 
depicted. β-actin served as loading control. 
 
Supplemental Fig. 9: Reactivation of AKAP12β in primary glioblastoma cells by 
demethylating drug treatment. Primary glioblastoma cell lines NCH82, NCH89 and NCH440 
were treated with 0µmol/l (-DAC) or 2µmol/l (+DAC) 5-aza-2’-deoxycytidine for 72h (see 
also Fig. 5). Re-expression of AKAP12β transcript relative to ACTB, GAPDH and HPRT1 
after 72h 5-aza-2’-deoxycytidine treatment.  
 
 
 
 
Table 1: Summary of tissue specimens and patient data  
 
Normal CNS 
tissue 
Pilocytic 
astrocytoma 
WHO°I 
Diffuse 
astrocytoma 
WHO°II 
Anaplastic 
astrocytoma 
WHO°III 
Glioblastoma 
WHO°IV 
Recurrence of 
glioblastoma 
Infiltration zone  
of glioblastoma 
Male/female 13/10 17/9 21/16 32/20 46/33 20/11 14/11 
Median age (range) 57 (1-92) 19.0 (3-56) 38.0 (23-77) 42.5 (19-76) 59 (23-88) 57 (27-69) 64 (23-77) 
Specimens (n) 23 26 37 52 79 31 25 
Karnofsky median (range)  100 (90-100) 90 (60-100) 90 (40-90) 90 (50-100)   
Tumor localisation 
(supratentorial/infratentorial) 
 11/15 35/2 52/0 79/0 31/0 25/0 
Complete resection 
(% of cases) 
 46.0 32.4 32.7 38.0   
Edema score 
(no/moderate/strong) 
 10/1/1 20/11/3 10/25/15 1/15/50   
median follow-up (range) 
in months 
 
50.3 
(2.4-113.1) 
41.1 
(1.1-150.9) 
24.4 
(0.5-125.7) 
9.8 
(0.5-70.3) 
  
mIDH1 (R132H) (mut/wt)  0/26 16/19 24/26 2/74   
 
